ARTICLE | Clinical News
HGS-ETR2: Interim Phase I data
April 25, 2005 7:00 AM UTC
Interim data from an open-label, dose-escalation, U.S. Phase I trial in 19 evaluable patients showed that HGS-ETR2 was well tolerated at doses up to 3 mg/kg and maximum tolerated dose had not been rea...